Skip to content

The efficacy of 68Ga-Pentixafor-PETCT comparing with AVS in the typing diagnosis of primary aldosteronism

The efficacy of 68Ga-Pentixafor-PETCT comparing with AVS in the typing diagnosis of primary aldosteronism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062844
Enrollment
Unknown
Registered
2022-08-20
Start date
2022-08-20
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

Gold Standard:Captopril challenge test, saline infusion test, bilateral adrenal venous sampling, pathological results, postoperative clinical and biochemical results.
Index test:68GA-Pentixafor&#32
was&#32
injected&#32
intravenously,&#32
the&#32
SUV&#32
of&#32
organs&#32
glands).

Sponsors

Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. Diagnosis of primary aldosteronism; 3. Willingness and conditions for surgery.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients with other secondary hypertension diseases; 3. Severe heart and liver dysfunction; 4. Serum creatinine > 265 umol/L, serum potassium > 5.5 mmol/L; 5. Taking diuretics or stopping diuretics for less than 4 weeks; 6. Other serious diseases (considered not suitable for screening by the investigator).

Design outcomes

Primary

MeasureTime frame
Maximal Standardized Uptake Value (SUVmax);

Countries

China

Contacts

Public ContactSu xin

The Second Xiangya Hospital of Central South University

suxin71@csu.edu.cn+86 13808457300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026